Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Oxaliplatin
Drug ID BADD_D01633
Description Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
Indications and Usage Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Marketing Status approved; investigational
ATC Code L01XA03
DrugBank ID DB00526
KEGG ID D01790
MeSH ID D000077150
PubChem ID 9887053
TTD Drug ID D0Y3ME
NDC Product Code 0703-3986; 13808-502; 0955-1733; 25021-233; 68083-171; 72603-101; 0955-1727; 57884-0017; 63592-0700; 50742-406; 55150-332; 67184-0501; 68083-170; 68083-176; 0955-1731; 72659-865; 43066-014; 68001-468; 71288-101; 82920-704; 16729-332; 45963-611; 67184-0502; 67184-0509; 0781-3317; 0781-9317; 67457-469; 0703-3985; 54875-0006; 67184-0510; 67457-442; 68083-314; 72266-126; 0781-3315; 50742-405; 71288-149; 72266-162; 0781-9315; 55150-331; 61703-363; 63323-750; 67184-0508; 72266-125; 72266-161; 72603-301; 79672-825; 0955-1725; 53104-7649; 67184-0007; 68554-0083; 60505-6132; 68083-177; 79672-826; 14778-0404; 49812-0075; 43066-018
UNII 04ZR38536J
Synonyms Oxaliplatin | Oxalato-(1,2-cyclohexanediamine)platinum II | Oxaliplatin, (SP-4-2-(1R-trans))-isomer | L-OHP Cpd | Platinum(II)-1,2-cyclohexanediamine Oxalate | 1,2-Diaminocyclohexane Platinum Oxalate | 1,2 Diaminocyclohexane Platinum Oxalate | 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | Oxaliplatine | Eloxatine | Eloxatin | Oxaliplatin, (SP-4-3-(cis))-isomer | ACT 078 | ACT-078 | ACT078 | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) | Oxaliplatin, (SP-4-2-(1S-trans))-isomer
Chemical Information
Molecular Formula C8H14N2O4Pt
CAS Registry Number 61825-94-3
SMILES C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neuronal neuropathy17.09.03.0190.000168%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000112%Not Available
Neuromyotonia10.04.05.008; 17.05.03.016; 16.32.01.008; 15.05.03.0330.000504%Not Available
Encephalitis autoimmune17.06.05.002; 16.32.01.006; 10.04.10.0120.000112%Not Available
Diabetic metabolic decompensation05.07.03.003; 14.07.03.0030.000168%Not Available
Noninfective epididymitis21.09.02.0040.000560%Not Available
Bone marrow infiltration01.05.01.0180.000112%Not Available
Toxic leukoencephalopathy17.13.02.012; 12.03.01.0590.000168%Not Available
Disorganised speech19.19.02.005; 17.02.08.0170.000224%Not Available
Pseudocirrhosis16.32.03.027; 09.01.04.0090.000112%Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.0350.000504%Not Available
Non-cirrhotic portal hypertension24.08.06.003; 09.01.06.0190.000616%Not Available
Tongue discomfort07.14.02.0190.000280%Not Available
Administration site pain08.02.04.029; 12.07.04.0290.000224%Not Available
Behaviour disorder19.01.01.0050.000112%Not Available
Catheter site bruise24.07.06.027; 23.03.11.029; 12.07.02.014; 08.02.02.0140.000112%Not Available
Catheter site swelling08.02.02.005; 12.07.02.0050.000280%Not Available
Catheter site vesicles23.03.01.032; 12.07.02.030; 08.02.02.0300.000168%Not Available
Ductal adenocarcinoma of pancreas16.13.10.006; 07.21.09.0110.000224%Not Available
Fixed eruption08.01.06.025; 23.03.05.008; 10.01.01.0370.000112%Not Available
Focal dyscognitive seizures17.12.02.0050.000168%Not Available
Gallbladder rupture12.01.17.005; 09.03.02.0120.000224%Not Available
Haemoperitoneum24.07.02.065; 12.01.17.007; 07.07.02.0070.000168%Not Available
Haemophagocytic lymphohistiocytosis01.05.01.026; 16.32.03.038; 10.02.01.0770.000616%Not Available
Hemiparaesthesia17.02.06.0450.000448%Not Available
Hepatic cytolysis09.01.07.0360.000616%Not Available
Hyperleukocytosis01.02.01.0180.000280%Not Available
Hypersensitivity pneumonitis22.01.01.027; 10.01.03.0560.000168%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.001287%Not Available
Infusion related hypersensitivity reaction12.02.05.055; 10.01.03.0580.000168%Not Available
The 23th Page    First    Pre   23 24    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene